MANILA – Pinag-aaralan na rin ng Department of Science and Technology (DOST) ang herbal medicines na lagundi at tawa-tawa bilang posibleng gamot laban sa coronavirus disease (COVID-19).
Ayon kay Dr. Jaime Montoya, Executive Director ng DOST-Philippine Council for Health Research and Development (PCHRD), nagsimula nang lumakad ang clinical trials ng bansa para sa naturang mga gamot.
“Output of these studies include clinical data on safety and efficacy against COVID-19 of herbal formulations like lagundi and tawa-tawa which have been reported to have anti-thrombocytopenic, anti-viral, and/or anti-inflmmatory activity,” ayon sa opisyal.
Batay sa huling datos ng DOST-PCHRD, as of April 23, mayroon ng 203 indibidwal na sumali sa pag-aaral ng lagundi.
Sa Hulyo naman inaasahang matatapos ang implementasyon ng pag-aaral sa tawa-tawa.
“Results of the projects can determine if lagundi and tawa-tawa can provide symptomatic relief to COVID-19 patients, as this can be added to the current standard of treatment.”
LOOK: DOST-PHCRD's Dr. Jaime Montoya gives updates on the clinical trials of herbal medicines lagundi and tawa-tawa against COVID-19. | @BomboRadyoNews pic.twitter.com/s3eW6cgnl4
— Christian Yosores (@chrisyosores) April 29, 2021
Bukod sa herbal medicines, pinag-aaralan din daw ng mga dalubhasa ng ahensya ang formulation ng “methylprednisolone sodium succinate – procaine hydrochloride” bilang injectable dosage.
Target daw ng mga scientist na makabuo ng potensyal na antiviral treatment laban sa COVID-19.
“Currently, the project team is coordinating with potential collaborators in Taiwan for the invitro antiviral testing of the drug against SARS-CoV-2.”
Patuloy din ang pag-aaral ng Science department sa virgin coconut oil, convalescent plasma at drug supplement na melatonin, bilang posibleng therapy at treatment sa mga pasyente ng coronavirus.
As of April 15, mayroon ng 42 participants na naka-enroll sa pag-aaral ng melatonin.
“(Convalescent plasma study) aims to evaluate the safety and efficacy treatment with anti-SARS-CoV-2 convalescent plasma in preventing disease progression among hospitalized patients with COVID-19.”
“The DOST-PCHRD ensures that our Filipino scientists will always find means to prove what they want to prove, and the council will support them, whether it be through funding or partnership.”
